Premium
Sitagliptin Treatment After Total Pancreatectomy With Islet Autotransplantation: A Randomized, Placebo‐Controlled Study
Author(s) -
Bellin M. D.,
Beilman G. J.,
Dunn T. B.,
Pruett T. L.,
Sutherland D. E. R.,
Chinnakotla S.,
Hodges J. S.,
Lane A.,
Ptacek P.,
Berry K. L.,
Hering B. J.,
Moran A.
Publication year - 2017
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.13979
Subject(s) - sitagliptin , medicine , sitagliptin phosphate , placebo , gastroenterology , endocrinology , insulin , urology , dipeptidyl peptidase 4 inhibitor , diabetes mellitus , type 2 diabetes , metformin , pathology , alternative medicine
Insulin independence after total pancreatectomy and islet autotransplant ( TPIAT ) for chronic pancreatitis is limited by a high rate of postprocedure beta cell apoptosis. Endogenous glucagon‐like peptide‐1 and glucose‐dependent insulinotropic peptide, which are increased by dipeptidyl peptidase 4 inhibitor therapy (sitagliptin) may protect against beta cell apoptosis. To determine the effect of sitagliptin after TPIAT , 83 adult TPIAT recipients were randomized to receive sitagliptin (n = 54) or placebo (n = 29) for 12 months after TPIAT . At 12 and 18 months after TPIAT , participants were assessed for insulin independence; metabolic testing was performed with mixed meal tolerance testing and frequent sample intravenous glucose tolerance testing. Insulin independence did not differ between the sitagliptin and placebo groups at 12 months (42% vs. 45%, p = 0.82) or 18 months (36% vs. 44%, p = 0.48). At 12 months, insulin dose was 9.0 (standard error 1.7) units/day and 7.9 (2.2) units/day in the sitagliptin and placebo groups, respectively (p = 0.67) and at 18 months 10.3 (1.9) and 7.1 (2.6) units/day, respectively (p = 0.32). Hemoglobin A 1c levels and insulin secretory measures were similar in the two groups, as were adverse events. In conclusion, sitagliptin could be safely administered but did not improve metabolic outcomes after TPIAT .